Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-agent Velcade (bortezomib) in malignant pleural mesothelioma
2005-004420-39Phase 2Terminated
- Sponsor
- Cancer Trials Ireland
- Start
- Jan 2006
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in pleural mesothelioma, sponsored by Cancer Trials Ireland. Primary endpoint: Objective tumour response rate. Started Jan 2006; status: terminated.
02
Drugs
bortezomib
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2005-004420-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004420-39.